

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 2

In the Claims

Please amend the claims by replacing all prior versions, and listings, of claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1-15. (canceled)

16. (currently amended) A pharmaceutical composition ~~for the treatment of an autoimmune disease,~~ comprising a ~~therapeutically effective~~ an amount of a terpolymer effective to treat an autoimmune disease, wherein the terpolymer comprising three different amino acids consists essentially of randomly polymerized tyrosine, alanine and lysine ~~randomly polymerized into a polypeptide,~~ and a pharmaceutically acceptable carrier, ~~wherein said three different amino acids are selected from the group of tyrosine, alanine and lysine.~~

17. (canceled)

18. (currently amended) The pharmaceutical composition of Claim ~~17~~ 16, wherein said terpolymer is substantially free of glutamic acid.

19. (currently amended) The pharmaceutical composition of Claim ~~17~~ 16, wherein said tyrosine is present in a mole fraction of about 0.005 to about 0.250; said alanine is present in a mole fraction of about 0.3 to about 0.6; and lysine is present in a mole fraction of about 0.1 to about 0.5.

20. (currently amended) The pharmaceutical composition of Claim ~~17~~ 16, wherein said tyrosine is present in a mole fraction of about 0.10, said alanine is present in a mole fraction

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 3

of about 0.54, and said lysine is present in a mole fraction of about 0.35.

21-31. (canceled)

32. (original) The pharmaceutical composition of Claim 16 wherein said terpolymer has a molecular weight of about 2,000 to about 40,000 daltons.

33. (original) The pharmaceutical composition of Claim 16 wherein said terpolymer has a molecular weight of about 4,000 to about 9,000 daltons.

34. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a B cell mediated autoimmune disease.

35. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a T cell mediated autoimmune disease.

36. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is an arthritic condition.

37. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is a demyelinating disease.

38. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is an inflammatory disease.

39. (original) The pharmaceutical composition of Claim 16, wherein said autoimmune disease is multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, chronic

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 4

immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

40-46. (canceled)

157. (new) A method for treating a subject afflicted with an autoimmune disease which comprises administering to the subject an amount of a terpolymer effective to treat the autoimmune disease, wherein the terpolymer consists essentially of randomly polymerized tyrosine, alanine and lysine.

158. (new) The method of claim 157, wherein the autoimmune disease is multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, rheumatoid arthritis, or systemic lupus erythematosus.

159. (new) The method of claim 158, wherein the autoimmune disease is multiple sclerosis.

160. (new) The method of claim 158, wherein the autoimmune disease is rheumatoid arthritis.

161. (new) The method of claim 160, wherein the amount of the terpolymer is at least 5 mg/day.

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 5

162. (new) The method of claim 161, wherein the amount of the terpolymer is at least 10 mg/day.
163. (new) The method of claim 162, wherein the amount of the terpolymer is at least 15 mg/day.
164. (new) The method of claim 163, wherein the amount of the terpolymer is at least 20 mg/day.
165. (new) The method of claim 160, wherein the amount of the terpolymer is 25-400 µg/kg of the subject per day.